Patients with chronic myeloid leukemia develop resistance to both first-generation and
second-generation tyrosine kinase inhibitors (TKIs) as a result of mutations in the kinase …

Abstract BCR-ABL1 kinase domain (KD) mutation status is considered to be an important
element of clinical decision algorithms for chronic myeloid leukemia (CML) patients who do …

BCR-ABL1 compound mutations can confer high-level resistance to imatinib and other ABL1
tyrosine kinase inhibitors (TKIs). The third-generation ABL1 TKI ponatinib is effective against …

BCR‐ABL protein is one of the most potent target to treat chronic myeloid leukemia (CML).
Apart from other mutations, T315I is especially challenging as it confers resistance to all first …

Genomic instability is a hallmark of chronic myeloid leukemia in chronic phase (CML-CP)
resulting in BCR-ABL1 mutations encoding resistance to tyrosine kinase inhibitors (TKIs) …

The development of tyrosine kinase inhibitors (TKIs) has led to extended lifespans for many
patients with chronic myelogenous leukemia (CML). However, 20% to 30% of patients fail to …

Optimal use of current therapeutic opportunities for chronic myeloid leukemia patients
requires integration of clinical and laboratory monitoring. Assessment of molecular response …

In chronic myeloid leukemia (CML) and Philadelphia-positive (Ph+) acute lymphoblastic
leukemia (ALL) patients who fail imatinib treatment, BCR-ABL1 mutation profiling by Sanger …

Chronic myeloid leukemia (CML) is the paradigm for targeted cancer therapy. RT-qPCR is
the gold standard for monitoring response to tyrosine kinase-inhibitor (TKI) therapy based on …

Background Imatinib-resistant chronic myeloid leukemia (CML) patients receiving second-
line tyrosine kinase inhibitor (TKI) therapy with dasatinib or nilotinib have a higher risk of …